More data needed on potential link between GLP1R agonists and GU cancers

In this video, Laura Bukavina, MD, MPH, shares the take-home message from the European Urology Oncology paper, “Association Between GLP1R Agonists and Prostate, Kidney, and Bladder Cancers.” Bukavina is an assistant professor urologic oncology at the Cleveland Clinic Glickman Urological & Kidney Institute in Cleveland, Ohio.

Transcription:

What is the take-home message for the practicing urologist?

I think [these are] important data to [give to] your patients. I think this is an association study; it's important to understand that these are just associations that we found. It's not definitive data, but for the urologists to be aware that a lot of the medications that we typically don't manage potentially could be increasing risk of kidney, bladder, and prostate cancer and for the patients to be aware that this is a new medication. A lot of patients are getting started on this medication, and we really don't know the long-term effects and potential associations with cancer, so we kind of have to hold tight until we get more data. I think these are great preliminary data to potentially lead the way of maybe doing more actual testing within the lab or potentially doing some prospective studies, which have been done in colorectal and heart disease.

This transcription was edited for clarity.